Terms: = Bone cancer AND SMARCB1, Ini1, 6598, ENSG00000099956, Snr1, SNF5L1, RDT, BAF47, hSNFS, SNF5, INI1, Sfh1p, Q12824 AND Prognosis
21 results:
1. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
2. smarcb1-Deficient Skull Base Chondrosarcoma with 12p Duplication Presenting as Somatic-Type Malignancy Arising from Metastatic Seminoma.
Argyris PP; Challa B; Satturwar S; VanKoevering KK; Wakely PE
Head Neck Pathol; 2024 Jan; 18(1):1. PubMed ID: 38236556
[TBL] [Abstract] [Full Text] [Related]
3. CRISPR-Cas9 screening identified lethal genes enriched in necroptosis pathway and of prognosis significance in osteosarcoma.
Cheng L; Xiong W; Li S; Wang G; Zhou J; Li H
J Gene Med; 2023 Dec; 25(12):e3563. PubMed ID: 37421290
[TBL] [Abstract] [Full Text] [Related]
4. smarcb1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma.
Guo T; Wei R; Dean DC; Hornicek FJ; Duan Z
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34984436
[TBL] [Abstract] [Full Text] [Related]
5. Chordomas: A review with emphasis on their pathophysiology, pathology, molecular biology, and genetics.
Karpathiou G; Dumollard JM; Dridi M; Dal Col P; Barral FG; Boutonnat J; Peoc'h M
Pathol Res Pract; 2020 Sep; 216(9):153089. PubMed ID: 32825957
[TBL] [Abstract] [Full Text] [Related]
6. Epithelioid rhabdomyosarcoma: Report of the first case in the jaw.
de Aguiar MCF; de Noronha MS; Silveira RL; Araújo JAD; Werkema FS; Bell D; Caldeira PC
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Nov; 130(5):e308-e315. PubMed ID: 32173396
[TBL] [Abstract] [Full Text] [Related]
7. [Chordoma: is there a molecular basis for diagnosis and treatment?].
Scheipl S; Igrec J; Leithner A; Smolle M; Haybäck J; Liegl B
Pathologe; 2020 Mar; 41(2):153-162. PubMed ID: 32100085
[TBL] [Abstract] [Full Text] [Related]
8. The prognostic role of BRAF and WNT pathways activation in kinase inhibitors-naïve clinical stage III cutaneous melanoma.
Kowalik A; Jurkowska M; Mierzejewska E; Ługowska I; Gos A; Szumera-Ciećkiewicz A; Zięba S; Koseła-Paterczyk H; van der Oord J; Dębiec-Rychter M; Szamotulska K; Siedlecki J; Rutkowski P
Melanoma Res; 2020 Aug; 30(4):348-357. PubMed ID: 32073511
[TBL] [Abstract] [Full Text] [Related]
9. smarcb1-Deficient Sinonasal Carcinoma: Systematic Review and Case Report.
Parsel SM; Jawad BA; McCoul ED
World Neurosurg; 2020 Apr; 136():305-310. PubMed ID: 32001406
[TBL] [Abstract] [Full Text] [Related]
10. [smarcb1 (ini1)-deficient sinonasal carcinoma: a clinicopathological analysis of six cases].
Tang SJ; Zhai CW; Yuan CC; Zhang JH; Wang SY
Zhonghua Bing Li Xue Za Zhi; 2020 Jan; 49(1):47-51. PubMed ID: 31914534
[No Abstract] [Full Text] [Related]
11. Future directions in soft tissue sarcoma treatment.
Hall F; Villalobos V; Wilky B
Curr Probl Cancer; 2019 Aug; 43(4):300-307. PubMed ID: 31229264
[TBL] [Abstract] [Full Text] [Related]
12. Chemoradiotherapy for Unresectable ini1-negative Chordoma in a Child.
Miyahara H; Nodomi S; Umeda K; Itasaka S; Waki K; Imai T
J Pediatr Hematol Oncol; 2020 Jan; 42(1):65-68. PubMed ID: 30281526
[TBL] [Abstract] [Full Text] [Related]
13. [Rare primary proximal epithelioid sarcoma in skull base: clinical analysis of four cases].
Duan ZJ; Yao K; Qu YM; Ren M; Zhang YL; Qi XL
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Apr; 53(4):263-269. PubMed ID: 29747250
[No Abstract] [Full Text] [Related]
14. Extra-axial chordoma: a clinicopathologic analysis of six cases.
Righi A; Sbaraglia M; Gambarotti M; Cocchi S; Drago G; Casadei R; Picci P; Vanel D; Dei Tos AP
Virchows Arch; 2018 Jun; 472(6):1015-1020. PubMed ID: 29560513
[TBL] [Abstract] [Full Text] [Related]
15. snf5 as a prognostic factor in skull base chordoma.
Li M; Zhai Y; Bai J; Wang S; Gao H; Li C; Gui S; Du J; Zhang Y
J Neurooncol; 2018 Mar; 137(1):139-146. PubMed ID: 29222701
[TBL] [Abstract] [Full Text] [Related]
16. Proximal-Type Epithelioid Sarcoma in Skull Base: a Pathological Diagnosis Challenge with Other Intracranial Tumors.
Zejun D; Kun Y; Dehong L; Xueling Q
Pathol Oncol Res; 2019 Jan; 25(1):201-208. PubMed ID: 29076075
[TBL] [Abstract] [Full Text] [Related]
17. [Poorly-differentiated chordoma with ini1 loss: a clinicopathologic study].
Feng JY; Chen L; Ma YY; Yang HW; Chen L
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):695-698. PubMed ID: 29050071
[No Abstract] [Full Text] [Related]
18. Histology and grading are important prognostic factors in synovial sarcoma.
Bianchi G; Sambri A; Righi A; Dei Tos AP; Picci P; Donati D
Eur J Surg Oncol; 2017 Sep; 43(9):1733-1739. PubMed ID: 28579008
[TBL] [Abstract] [Full Text] [Related]
19. Malignant rhabdoid transformation of a longstanding, aggressive, and recurrent orbital angiomyxoma.
Jakobiec FA; Callahan AB; Stagner AM; Lee NG; Rashid A; Mendoza P; Grove A; Freitag SK
Surv Ophthalmol; 2015; 60(2):166-76. PubMed ID: 25595060
[TBL] [Abstract] [Full Text] [Related]
20. Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression, retention of ini1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases.
Fanburg-Smith JC; Auerbach A; Marwaha JS; Wang Z; Santi M; Judkins AR; Rushing EJ
Ann Diagn Pathol; 2010 Feb; 14(1):8-14. PubMed ID: 20123451
[TBL] [Abstract] [Full Text] [Related]
[Next]
